170 related articles for article (PubMed ID: 30111881)
1. Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece.
Konstanta I; Fostira F; Apostolou P; Stratikos E; Kalfakakou D; Pampanos A; Kollia P; Papadimitriou C; Konstantopoulou I; Yannoukakos D
J Hum Genet; 2018 Nov; 63(11):1149-1158. PubMed ID: 30111881
[TBL] [Abstract][Full Text] [Related]
2. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
[TBL] [Abstract][Full Text] [Related]
3. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
[TBL] [Abstract][Full Text] [Related]
4. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
[TBL] [Abstract][Full Text] [Related]
5. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.
Chen X; Li Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2018 Oct; 29(10):2046-2051. PubMed ID: 30165555
[TBL] [Abstract][Full Text] [Related]
6. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
[TBL] [Abstract][Full Text] [Related]
7. Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.
Thompson ER; Rowley SM; Sawyer S; kConfab ; Eccles DM; Trainer AH; Mitchell G; James PA; Campbell IG
PLoS One; 2013; 8(1):e54772. PubMed ID: 23372765
[TBL] [Abstract][Full Text] [Related]
8. A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
Pelttari LM; Kiiski J; Nurminen R; Kallioniemi A; Schleutker J; Gylfe A; Aaltonen LA; Leminen A; Heikkilä P; Blomqvist C; Bützow R; Aittomäki K; Nevanlinna H
J Med Genet; 2012 Jul; 49(7):429-32. PubMed ID: 22652533
[TBL] [Abstract][Full Text] [Related]
9. Germline RAD51C mutations in ovarian cancer susceptibility.
Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
[TBL] [Abstract][Full Text] [Related]
10. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
11. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D.
Yang X; Song H; Leslie G; Engel C; Hahnen E; Auber B; Horváth J; Kast K; Niederacher D; Turnbull C; Houlston R; Hanson H; Loveday C; Dolinsky JS; LaDuca H; Ramus SJ; Menon U; Rosenthal AN; Jacobs I; Gayther SA; Dicks E; Nevanlinna H; Aittomäki K; Pelttari LM; Ehrencrona H; Borg Å; Kvist A; Rivera B; Hansen TVO; Djursby M; Lee A; Dennis J; Bowtell DD; Traficante N; Diez O; Balmaña J; Gruber SB; Chenevix-Trench G; Investigators K; Jensen A; Kjær SK; Høgdall E; Castéra L; Garber J; Janavicius R; Osorio A; Golmard L; Vega A; Couch FJ; Robson M; Gronwald J; Domchek SM; Culver JO; de la Hoya M; Easton DF; Foulkes WD; Tischkowitz M; Meindl A; Schmutzler RK; Pharoah PDP; Antoniou AC
J Natl Cancer Inst; 2020 Dec; 112(12):1242-1250. PubMed ID: 32107557
[TBL] [Abstract][Full Text] [Related]
12. Loss of function germline mutations in RAD51D in women with ovarian carcinoma.
Wickramanayake A; Bernier G; Pennil C; Casadei S; Agnew KJ; Stray SM; Mandell J; Garcia RL; Walsh T; King MC; Swisher EM
Gynecol Oncol; 2012 Dec; 127(3):552-5. PubMed ID: 22986143
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and survival analysis of Chinese ovarian cancer patients with RAD51D germline mutations.
Yao H; Li N; Yuan H
BMC Cancer; 2022 Dec; 22(1):1337. PubMed ID: 36544182
[TBL] [Abstract][Full Text] [Related]
14. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
Suszynska M; Klonowska K; Jasinska AJ; Kozlowski P
Gynecol Oncol; 2019 May; 153(2):452-462. PubMed ID: 30733081
[TBL] [Abstract][Full Text] [Related]
15. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
[TBL] [Abstract][Full Text] [Related]
16. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C;
J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436
[TBL] [Abstract][Full Text] [Related]
18. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:
Hanson H; Kulkarni A; Loong L; Kavanaugh G; Torr B; Allen S; Ahmed M; Antoniou AC; Cleaver R; Dabir T; Evans DG; Golightly E; Jewell R; Kohut K; Manchanda R; Murray A; Murray J; Ong KR; Rosenthal AN; Woodward ER; Eccles DM; Turnbull C; Tischkowitz M; ; Lalloo F
J Med Genet; 2023 May; 60(5):417-429. PubMed ID: 36411032
[TBL] [Abstract][Full Text] [Related]
19. Inherited Mutations in Women With Ovarian Carcinoma.
Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants.
Delgado L; Fernández G; Grotiuz G; Cataldi S; González A; Lluveras N; Heguaburu M; Fresco R; Lens D; Sabini G; Muse IM
Breast Cancer Res Treat; 2011 Jul; 128(1):211-8. PubMed ID: 21190077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
